EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project

Marian Schini iD, Li-Yung Lui, Tatiane Vilaca iD, Susan K Ewing, Austin Thompson iD, Douglas C Bauer, Mary L Bouxsein, Dennis M Black, Richard Eastell iD

Journal of Bone and Mineral Research · 15.03.2025 · 40 (3) · 307-314

DOI: 10.1093/jbmr/zjae201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bone and Mineral Research, online erschienen am 16.12.2024. Verfasst von Marian Schini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, S10 2TN, Sheffield, United Kingdom. Hauptthemen laut MEDLINE: Bone Density, Randomized Controlled Trials as Topic, Fractures, Bone. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, FDA HHS, American Society for Bone Mineral Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have proposed to the Food and Drug Administration (FDA) that treatment-related increases in total hip BMD (TH BMD) at 2 yr could be a surrogate endpoint for fracture risk reduction in clinical trials. The qualification of a surrogate includes a strong association of the surrogate with the clinical outcome. We compiled a large database of individual patient data (IPD) through the Foundation for the National Institutes of Health-American Society for Bone and Mineral Research- A Study to Advance BMD as a Regulatory Endpoint (FNIH-ASBMR-SABRE) project, and this analysis aimed to assess the relationship between baseline BMD and fracture risk in the placebo groups. We estimated the association of baseline TH, femoral neck (FN), and lumbar spine (LS) BMD with fracture risk using IPD from the combined placebo groups, which included data from 46 666 placebo participants in 25 RCTs. We estimated the relative risk (RR) of fracture per SD decrease in baseline BMD using logistic regression models for radiographic vertebral fractures and proportional hazards models for hip, non-vertebral, “all,” and “all clinical” fractures. Total person-years in the combined placebo groups was 250 662 (mean baseline age 70.2 ± 7.2 yr, mean TH BMD T-score −1.97 ± 0.90). We observed significant relationships between baseline TH BMD and vertebral (RR = 1.55/SD), hip (RR = 2.27), non-vertebral (RR = 1.31), all (RR = 1.43), and all clinical (RR = 1.35) fracture risk. Fracture risk estimates were similar for FN BMD and after adjustment for age, race, and study. Fracture incidence increased with decreasing TH BMD quintile, confirming the strong graded association between TH BMD and fracture risk. There was a strong relationship between LS BMD and vertebral fracture risk (RR = 1.56/SD), but only a weak association with non-vertebral (RR = 1.07) and no association with hip (RR = 1.01) fracture risk. These data support the very strong relationship between hip BMD and fracture risk and provide supporting rationale for change in TH BMD as a surrogate for fracture risk reduction in future RCTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityRandomized Controlled Trials as TopicFractures, BoneHumansFemaleMaleIncidenceAgedMiddle AgedPlacebosSpinal FracturesFemur Neck

Stichwörter der Autor:innen

Bone mineral densitySABREbaseline BMDfracture riskosteoporosis

Substanzen

Placebos

Autor:innen und Institutionen

  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, S10 2TN, Sheffield, United Kingdom.
  • California Pacific Medical Center Research Institute, San Francisco, 94158, CA, United States.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, 94158, CA, United States.
  • Department of Medicine, University of California, San Francisco, 94158, CA, United States.
  • Department of Orthopedic Surgery, Harvard Medical School, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, 02215, MA, United States.

ORCID-Profile: Marian Schini, Tatiane Vilaca, Austin Thompson, Richard Eastell

Förderung

  • NIAMS NIH HHS
  • FDA HHS
  • American Society for Bone Mineral Research
  • Food and Drug Administration

Zitieren

APA

Schini, M., Lui, L. Y., Vilaca, T., Ewing, S. K., Thompson, A., Bauer, D. C., Bouxsein, M. L., Black, D. M., & Eastell, R. (2025). The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project. Journal of Bone and Mineral Research, 40(3), 307-314. https://doi.org/10.1093/jbmr/zjae201

Vancouver

Schini M, Lui LY, Vilaca T, Ewing SK, Thompson A, Bauer DC, et al. The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project. Journal of Bone and Mineral Research. 2025;40(3):307-314. doi:10.1093/jbmr/zjae201

BibTeX
@article{Schini2025,
  author = {Schini, Marian and Lui, Li-Yung and Vilaca, Tatiane and Ewing, Susan K and Thompson, Austin and Bauer, Douglas C and Bouxsein, Mary L and Black, Dennis M and Eastell, Richard},
  title = {The relationship between baseline bone mineral density and fracture incidence in the placebo groups of randomized controlled trials using individual patient data from the FNIH-ASBMR-SABRE project},
  journal = {Journal of Bone and Mineral Research},
  year = {2025},
  volume = {40},
  number = {3},
  pages = {307--314},
  doi = {10.1093/jbmr/zjae201}
}
Kostenlos starten →